...
首页> 外文期刊>Biochemistry >CRYSTAL STRUCTURES OF COMPLEXES OF A PEPTIDIC INHIBITOR WITH WILD-TYPE AND TWO MUTANT HIV-1 PROTEASES
【24h】

CRYSTAL STRUCTURES OF COMPLEXES OF A PEPTIDIC INHIBITOR WITH WILD-TYPE AND TWO MUTANT HIV-1 PROTEASES

机译:带有野生型和两种突变型HIV-1蛋白酶的肽抑制剂的复合物的晶体结构

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Crystal structures of the protease of human immunodeficiency virus type 1 (HIV-1) and two mutant proteases, V82D and V82N, have been determined. In all three cases the enzyme forms a complex with the peptidic inhibitor U-89360E. All structures have been determined to 2.3 Angstrom resolution and have satisfactory agreement factors: 0.173 for wild type, 0.175 for V82D, and 0.182 for V82N. Comparison of the three crystal structures provides explanations which are consistent with the known kinetic properties of these mutant enzymes with the U-89360E inhibitor [Lin, Y., Lin, X., Hong, L., Foundling, S., Heinrikson, R. L., Thaisrivongs, S., Leelamanit, W., Raterman, D., Shah, M., Dunn, B. M., & Tang, J. (1995) Biochemistry 34, 1143-1152]. Unfavorable van der Waals interactions between the inhibitor and the mutated side chains at position 82 are consistent with diminished affinity for the inhibitor by the mutant enzymes. If a mutation is potentially resistant to an inhibitor, the mutant enzyme should not only have an increased K-i for the inhibitor but should also preserve considerable catalytic capability. The V82D mutant possesses these qualities. In the V82D crystal structure, a water molecule, which connects the protease flap to the inhibitor, is missing or of low occupancy. Absence of this bridge may be important in determining catalytic capability. Moreover, mutation at position 82 induces change in two polypeptide backbone regions, 35-41 and 67-68, which may be related to protease flap mobility.
机译:已经确定了人类免疫缺陷病毒1型(HIV-1)的蛋白酶和两种突变型蛋白酶V82D和V82N的晶体结构。在这三种情况下,酶均与肽类抑制剂U-89360E形成复合物。所有结构均已确定为2.3埃分辨率,并具有令人满意的一致性:野生型0.173,V82D 0.175和V82N 0.182。三种晶体结构的比较提供了与这些突变酶与U-89360E抑制剂的已知动力学特性一致的解释[Lin,Y.,Lin,X.,Hong,L.,Foundling,S.,Heinrikson,RL ,Thaisrivongs,S.,Leelamanit,W.,Raterman,D.,Shah,M.,Dunn,BM,和Tang,J。(1995)Biochemistry 34,1143-1152]。抑制剂与82位突变侧链之间不利的范德华相互作用与突变酶对抑制剂的亲和力降低是一致的。如果突变可能对抑制剂具有抗性,则突变酶不仅应具有增加的抑制剂K-i值,而且还应保留相当大的催化能力。 V82D突变体具有这些特质。在V82D晶体结构中,将蛋白酶片与抑制剂连接的水分子缺失或占有率低。在确定催化能力时,不存在该桥可能很重要。而且,在位置82处的突变诱导两个多肽主链区域35-41和67-68的改变,这可能与蛋白酶皮瓣迁移率有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号